why choose us

First received: March 22, 2023

Clinical Trial: Characterization and Kinetic of Chemotherapy-induced Cardiovascular Toxicity in Breast Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Breast Cancer

Study Type: OBSERVATIONAL


Official Title: Characterization and Kinetic of Chemotherapy-induced Cardiovascular Toxicity in Breast Cancer - PROTECT-COEUR

Brief Summary: The combination of epirubicin-cyclophosphamide (EC) and paclitaxel (Tax) is one of the main chemotherapy treatments used in breast cancer patients.These treatments, which can be combined with anti-HER2 therapy using trastuzumab, are frequently associated with side effects including cardiac toxicity.However, this cardiac toxicity has only been demonstrated several months after treatment and using global indices such as ejection fraction.The assessment of myocardial dysfunction using regional deformations and the…

Read more